Type 2 Diabetes (The Market Access Environment – Current and Emerging Noninsulin Antidiabetic Agents) | Physician & Payer Forum | China | 2014
The increase in patient awareness and the longer life expectancies are driving the growth of the Chinese diabetes market. There is potentially great opportunity for multinational pharmaceutical companies seeking to penetrate the antidiabetic therapies market in China. However, many drugs that are launched in the West, such as SGLT-2 inhibitors and long-acting release GLP-1 analogues, are not yet available in China, and the most recently launched DPP-IV inhibitors and short-acting GLP-1 analogues are still optimizing uptake in this highly lucrative market. Navigating the road to reimbursement and optimizing market access are, therefore, challenging.
Related Market Assessment Reports
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
